drugset / Trial / NCT02251210

Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis

NCT02251210

Phase 2 Completed 404 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate efficacy and safety of 3 doses of BIIL 284 BS in active rheumatoid arthritis (RA) and determine the dose with most positive efficacy / safety ratio. Pharmacokinetic profile will be also obtained.

Timeline

Start
2001-05
Primary completion
2002-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject AMELUBANT Small molecule 5 mg Oral
Subject AMELUBANT Small molecule 25 mg Oral
Subject AMELUBANT Small molecule 75 mg Oral

Indications